Skip to content

Evaluation of the GlucoTrack, Non-Invasive Glucose Monitoring Device

Evaluation of the Performance and Use of the GlucoTrack(TM), Non-Invasive Glucose Monitoring Device

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00433758
Enrollment
142
Registered
2007-02-12
Start date
2006-12-31
Completion date
2008-12-31
Last updated
2008-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Keywords

Diabetes, Blood glucose monitoring, Non invasive Blood glucose monitoring

Brief summary

The purpose of this study is to demonstrate the performance of the GlucoTrack device (non invasive device) in measuring blood glucose levels

Detailed description

Diabetes is a leading cause of death in the Western World with medical costs increasing annually. There is no cure for diabetes, and blood glucose monitoring is a key component in diabetes treatment and management. Consistently high blood sugar levels can, over time, lead to complications such as blindness, kidney disease, heart disease, and nerve damage.In addition, low blood sugars may lead to immediate dangers. Self-monitoring of blood glucose levels is essential to the self-management of diabetes and has become widespread over the past decade. Blood glucose determinations are currently done by invasive methods (finger tip pricking), followed by measuring the blood drop characteristics. Currently, there is no commercially available reliable non-invasive glucose measurement device that being marketed. The GlucoTrack, non-invasive device for determining glucose levels based on the simultaneous measurement of three independent orthogonal parameters. The rationale for development of the device is to improve the patient's quality of life by providing a device that is easily used and provides a painless measurement method, thereby leading to higher compliance, and to better managed diabetes

Interventions

GT

Sponsors

Integrity Applications Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with Type 1, Type 2, or Gestational Diabetes * Above the age of 10

Exclusion criteria

* Does not meet inclusion criteria * Patients requiring dialysis * Participation in other clinical investigations within the previous month. * Pregnancy(excluding patients that intend to participate in the gestational group)

Design outcomes

Primary

MeasureTime frame
Clarke Error GridClarke Error Grid

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026